Exploring Metabolic Pathways of Anamorelin, a Selective Agonist of the Growth Hormone Secretagogue Receptor, via Molecular Networking
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwak, Young Beom | - |
dc.contributor.author | Seo, Jeong In | - |
dc.contributor.author | Yoo, Hye Hyun | - |
dc.date.accessioned | 2024-01-11T02:00:24Z | - |
dc.date.available | 2024-01-11T02:00:24Z | - |
dc.date.issued | 2023-12 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.issn | 1999-4923 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/117018 | - |
dc.description.abstract | In this study, we delineated the poorly characterized metabolism of anamorelin, a growth hormone secretagogue receptor agonist, in vitro using human liver microsomes (HLM), based on classical molecular networking (MN) and feature-based molecular networking (FBMN) from the Global Natural Products Social Molecular Networking platform. Following the in vitro HLM reaction, the MN analysis showed 11 neighboring nodes whose information propagated from the node corresponding to anamorelin. The FBMN analysis described the separation of six nodes that the MN analysis could not achieve. In addition, the similarity among neighboring nodes could be discerned via their respective metabolic pathways. Collectively, 18 metabolites (M1–M12) were successfully identified, suggesting that the metabolic pathways involved were demethylation, hydroxylation, dealkylation, desaturation, and N-oxidation, whereas 6 metabolites (M13a*-b*, M14a*-b*, and M15a*-b*) remained unidentified. Furthermore, the major metabolites detected in HLM, M1 and M7, were dissimilar from those observed in the CYP3A4 isozyme assay, which is recognized to be markedly inhibited by anamorelin. Specifically, M7, M8, and M9 were identified as the major metabolites in the CYP3A4 isozyme assay. Therefore, a thorough investigation of metabolism is imperative for future in vivo studies. These findings may offer prospective therapeutic opportunities for anamorelin. © 2023 by the authors. | - |
dc.format.extent | 14 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
dc.title | Exploring Metabolic Pathways of Anamorelin, a Selective Agonist of the Growth Hormone Secretagogue Receptor, via Molecular Networking | - |
dc.type | Article | - |
dc.publisher.location | 스위스 | - |
dc.identifier.doi | 10.3390/pharmaceutics15122700 | - |
dc.identifier.scopusid | 2-s2.0-85180691766 | - |
dc.identifier.wosid | 001130990600001 | - |
dc.identifier.bibliographicCitation | Pharmaceutics, v.15, no.12, pp 1 - 14 | - |
dc.citation.title | Pharmaceutics | - |
dc.citation.volume | 15 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 14 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | DRUG-METABOLISM | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | CACHEXIA | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordAuthor | anamorelin | - |
dc.subject.keywordAuthor | GHSR agonist | - |
dc.subject.keywordAuthor | LC-MS/MS | - |
dc.subject.keywordAuthor | metabolism | - |
dc.subject.keywordAuthor | molecular networking | - |
dc.identifier.url | https://www.scopus.com/record/display.uri?eid=2-s2.0-85180691766&origin=inward&txGid=7197504412257683235b19a6a559d176 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.